Bayer will present clinical data from on riociguat (Adempas), which is approved to treat pulmonary arterial hypertension (PAH), at the 2017 American Thoracic Society (ATS) International Conference, May 19-24 in Washington DC.

In addition, Bayer will share information about the development of an algorithm based on medical and procedural claims data to help identify patients at risk for developing chronic thromboembolic pulmonary hypertension (CTEPH).

Presentations include:

Rationale and Design of the REPLACE Trial: Riociguat rEplacing Phosphodiesterase 5 Inhibitor (PDE5i) Therapy evaLuated Against Continued PDE5i thErapy in Patients with Pulmonary Arterial Hypertension (PAH)

    • Sunday, May 21, 2017; 11:15 a.m. – 1:00 p.m.
    • Walter E. Washington Convention Center; Area O, Hall B-C
    • Presenter: Dr. Marius M. Hoeper, Hannover Medical School

Riociguat for the Treatment of Pulmonary Hypertension: Safety Data from the EXPERT Registry

    • Sunday, May 21, 2017; 11:15 a.m. – 1:00 p.m.
    • Walter E. Washington Convention Center; Area O, Hall B-C
    • Presenter: Dr Hans Klose, University Medical Center Hamburg-Eppendorf

Results of the Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 MOTION Study of Riociguat in Pulmonary Arterial Hypertension

    • Sunday, May 21, 2017; 11:15 a.m. – 1:00 p.m.
    • Walter E. Washington Convention Center; Area O, Hall B-C
    • Presenter: Dr Namita Sood, The Ohio State University

The Rationale for a Washout Period When Switching Patients from PDE5i to Riociguat

    • Sunday, May 21, 2017; 11:15 a.m. – 1:00 p.m.
    • Walter E Washington Convention Center; Area O, Hall B-C
    • Presenter: Dr Roxana Sulica, Mount Sinai Beth Israel

Development of a Claims-Based Algorithm to Identify Patients with Chronic Thromboembolic Pulmonary Hypertension

    • Sunday, May 21, 2017; 2:15 – 4:15 p.m.
    • Marriott Marquis Washington; Marquis Ballroom 9-10
    • Presenter: Simon Teal, Bayer

“Data presented at this year’s meeting represent Bayer’s continued commitment to improving our understanding of riociguat and its impact on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,” said Aleksandra Vlajnic, MD, Vice President of Medical Affairs at Bayer. “We also look forward to working with physicians to develop tools that may help accelerate time-to-diagnosis and support those living with these often underdiagnosed and undertreated conditions.”